FDA approves new drug for advanced kidney cancer
-
Last Update: 2020-07-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
the U.SFood and Drug Administration approved a new drug Wednesday to extend the survival of patients with advanced kidney cancerThe drug, called Torisel, is manufactured by Wyeth Pharmaceuticals in the United States to treat renal cell carcinoma, a specific type of advanced kidney cancerThe FDA said in a statement that clinical trials have shown that taking Torisel can prolong the survival of patients with renal cell carcinomaIt is the thirddrug approved by the FDA to fight kidney cancerin nearly a year and a half2
January 2005
February 2005, a new drug, Dorgimi, was approved for sale, which slows the progression of kidney cancerJanuary 2
,,the new drug Sutent was approved for the marketwith accelerated approval,the drug could reduce theof kidney cancertumor,later clinical application found that it can also delay thelesions oftumorsThe data showabout 50,000 people in the U.Sare diagnosed with kidney cell cancer each year,about 85 percent of kidney cancer in U.Sadults is kidney cell carcinoma(
reprinted from "Xinhuanet")
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
